Regenerative Medical Technology Group Inc Financials

RMTG

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Regenerative Medical Technology Group Inc (RMTG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RMTG FY2025 2026-06-09

Revenue growth is being outrun by a financing burden, leaving liquidity and debt servicing — not product margin — as the central operating constraint.

Revenue growth did not strengthen the model despite higher sales, because gross margin fell to 55.1% from 68.7%. With interest expense at $7.4M versus gross profit of $2.8M, the main drag sits in the capital structure, which also helps explain why FY2024's brief cash improvement was not durable.

The company is operating with extreme short-term balance-sheet pressure: $1.2M of current assets supports $36.8M of current liabilities. Because total liabilities already exceed the asset base by a wide margin, the balance sheet has little internal cushion, so this reads more like a funding-timing constraint than a simple sales shortfall.

The underlying operation is not consistently dropping incremental sales into cash. After a brief positive year, free cash flow fell to -$1.3M as operating cash slipped and capital spending rose to $603K, suggesting the business still needs reinvestment even before servicing its financing burden.

Financial Health Signals

Financial health score pending refresh

We are recalculating Regenerative Medical Technology Group Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Distress

-32.52

Regenerative Medical Technology Group Inc scores -32.52, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($394K) relative to total liabilities ($39.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

Regenerative Medical Technology Group Inc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.09x

For every $1 of reported earnings, Regenerative Medical Technology Group Inc generates $0.09 in operating cash flow (-$707K OCF vs -$7.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-0.1x

Regenerative Medical Technology Group Inc earns $-0.1 in operating income for every $1 of interest expense (-$867K vs $7.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.1M

YoY+24.2%

5Y CAGR+147.4%

Regenerative Medical Technology Group Inc generated $5.1M in revenue in fiscal year 2025. This represents an increase of 24.2% from the prior year.

EBITDA

-$586K

YoY-294.2%

Regenerative Medical Technology Group Inc's EBITDA was -$586K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 294.2% from the prior year.

Net Income

-$7.8M

YoY-40.4%

Regenerative Medical Technology Group Inc reported -$7.8M in net income in fiscal year 2025. This represents a decrease of 40.4% from the prior year.

EPS (Diluted)

$-0.62

YoY-40.9%

Regenerative Medical Technology Group Inc earned $-0.62 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 40.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$1.3M

YoY-306.1%

Regenerative Medical Technology Group Inc generated -$1.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 306.1% from the prior year.

Cash & Debt

$957K

YoY-17.9%

5Y CAGR+86.4%

Regenerative Medical Technology Group Inc held $957K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

13M

YoY+4.8%

5Y CAGR+3.9%

Regenerative Medical Technology Group Inc had 13M shares outstanding in fiscal year 2025. This represents an increase of 4.8% from the prior year.

Margins & Returns

Gross Margin

55.1%

YoY-13.6pp

5Y CAGR+34.9pp

Regenerative Medical Technology Group Inc's gross margin was 55.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 13.6 percentage points from the prior year.

Operating Margin

-17.0%

YoY-19.0pp

Regenerative Medical Technology Group Inc's operating margin was -17.0% in fiscal year 2025, reflecting core business profitability. This is down 19.0 percentage points from the prior year.

Net Margin

-153.2%

YoY-17.8pp

Regenerative Medical Technology Group Inc's net profit margin was -153.2% in fiscal year 2025, showing the share of revenue converted to profit. This is down 17.8 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$603K

YoY+179.7%

5Y CAGR+43.2%

Regenerative Medical Technology Group Inc invested $603K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 179.7% from the prior year.

RMTG Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$5.1M+24.2%	$4.1M+70.4%	$2.4M+57.5%	$1.5M+249.5%	$438K+695.0%	$55K
Cost of Revenue	$2.3M+78.3%	$1.3M+74.9%	$734K+12.4%	$653K+127.0%	$288K+554.7%	$44K
Gross Profit	$2.8M-0.4%	$2.8M+68.5%	$1.7M+91.1%	$877K+484.1%	$150K+1249.2%	$11K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$1.1M+40.3%	$798K+6.1%	$753K-90.8%	$8.2M+5389.6%	$149K+400.1%	$30K
Operating Income	-$867K-1168.2%	$81K+111.4%	-$715K	N/A	N/A	N/A
Interest Expense	$7.4M+32.0%	$5.6M-13.1%	$6.5M	N/A	$2.7M	N/A
Income Tax	-$1.6M-41.1%	-$1.2M+43.6%	-$2.1M-78.2%	-$1.2M+57.3%	-$2.7M	N/A
Net Income	-$7.8M-40.4%	-$5.6M+43.3%	-$9.8M-78.2%	-$5.5M+57.3%	-$12.9M	N/A
EPS (Diluted)	$-0.62-40.9%	$-0.44+44.3%	$-0.79-75.6%	$-0.45+59.8%	$-1.12	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$2.6M+67.9%	$1.6M+33.2%	$1.2M+20.0%	$984K-27.9%	$1.4M-9.7%	$1.5M+53.2%	$986K+24.3%	$793K
Cost of Revenue	$873K+10.2%	$792K+16.7%	$679K+70.7%	$398K-5.4%	$420K-20.8%	$531K+121.8%	$239K-10.2%	$266K
Gross Profit	$1.8M+126.6%	$779K+55.4%	$502K-14.4%	$586K-37.9%	$944K-3.7%	$980K+31.2%	$747K+41.8%	$527K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$476K+22.2%	$389K+40.2%	$278K+33.9%	$207K-15.5%	$246K+117.1%	$113K-57.2%	$264K+0.8%	$262K
Operating Income	$230K+175.0%	-$306K+31.3%	-$446K-78.2%	-$250K-285.3%	$135K-64.5%	$381K+1837.2%	$20K+109.2%	-$214K
Interest Expense	$2.2M+9.2%	$2.0M-42.5%	$3.5M+230.8%	$1.1M+17.8%	$896K-12.1%	$1.0M+12.6%	$906K-51.4%	$1.9M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$876K+37.1%	-$1.4M+68.0%	-$4.4M-233.4%	-$1.3M-71.8%	-$760K-19.1%	-$638K+28.1%	-$887K+57.3%	-$2.1M
EPS (Diluted)	$-0.07	N/A	$-0.35-250.0%	$-0.10-66.7%	$-0.06	N/A	$-0.07+58.8%	$-0.17

RMTG Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$4.5M+17.5%	$3.8M+32.7%	$2.9M-64.4%	$8.1M-13.2%	$9.3M+4134.9%	$220K
Current Assets	$1.2M-2.0%	$1.2M+117.1%	$575K-66.1%	$1.7M-43.9%	$3.0M+7000.3%	$43K
Cash & Equivalents	$957K-17.9%	$1.2M+119.7%	$531K-67.8%	$1.6M-44.8%	$3.0M+6902.7%	$43K
Inventory	$159K+1474.7%	$10K	N/A	N/A	N/A	N/A
Accounts Receivable	$44K+93.8%	$23K	N/A	N/A	N/A	N/A
Goodwill	$1.7M0.0%	$1.7M0.0%	$1.7M-71.1%	$5.8M0.0%	$5.8M	N/A
Total Liabilities	$39.2M+25.8%	$31.2M+26.4%	$24.7M+23.0%	$20.1M+24.9%	$16.1M+142.3%	$6.6M
Current Liabilities	$36.8M+27.1%	$29.0M+30.2%	$22.2M+85.4%	$12.0M+184.5%	$4.2M+361.3%	$914K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$34.7M-27.0%	-$27.4M-25.5%	-$21.8M-81.9%	-$12.0M-77.3%	-$6.8M-5.4%	-$6.4M
Retained Earnings	-$75.4M-11.6%	-$67.6M-9.0%	-$62.0M-18.8%	-$52.2M-11.8%	-$46.7M-38.1%	-$33.8M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$5.0M+11.6%	$4.5M-0.7%	$4.5M+0.7%	$4.5M+12.7%	$4.0M+4.2%	$3.8M	N/A	$3.1M
Current Assets	$1.6M+28.0%	$1.2M-19.0%	$1.5M-21.0%	$1.9M+31.9%	$1.4M+16.1%	$1.2M	N/A	$687K
Cash & Equivalents	$1.1M+10.9%	$957K-19.3%	$1.2M-26.5%	$1.6M+32.0%	$1.2M+4.9%	$1.2M+39.4%	$836K+35.5%	$617K
Inventory	$298K+87.2%	$159K+2.2%	$156K+47.5%	$106K+363.0%	$23K+125.7%	$10K	N/A	$7K
Accounts Receivable	$35K-20.5%	$44K-61.6%	$114K	N/A	N/A	$23K	N/A	N/A
Goodwill	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M	N/A	$1.7M
Total Liabilities	$40.6M+3.6%	$39.2M+13.5%	$34.6M+3.2%	$33.5M+4.4%	$32.1M+2.9%	$31.2M	N/A	$28.9M
Current Liabilities	$38.2M+3.7%	$36.8M+113.2%	$17.3M-43.4%	$30.5M+2.2%	$29.9M+3.1%	$29.0M	N/A	$26.4M
Long-Term Debt	N/A	N/A	N/A	$4	N/A	N/A	N/A	N/A
Total Equity	-$35.6M-2.5%	-$34.7M-15.6%	-$30.1M-3.6%	-$29.0M-3.2%	-$28.1M-2.8%	-$27.4M-2.4%	-$26.7M-3.4%	-$25.8M
Retained Earnings	-$76.2M-1.2%	-$75.4M-1.9%	-$74.0M-6.3%	-$69.6M-1.9%	-$68.3M-1.1%	-$67.6M	N/A	-$66.0M

RMTG Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$707K-183.1%	$851K+302.9%	-$419K+62.4%	-$1.1M+88.7%	-$9.9M-2960.8%	-$323K
Capital Expenditures	$603K+179.7%	$215K-44.1%	$386K+94.3%	$198K	N/A	$100K
Free Cash Flow	-$1.3M-306.1%	$635K+178.9%	-$805K+38.7%	-$1.3M	N/A	-$423K
Investing Cash Flow	-$603K-179.7%	-$215K+44.1%	-$386K-94.3%	-$198K-129.8%	$666K+480.8%	-$175K
Financing Cash Flow	$1.1M	N/A	-$310K-1391.4%	-$21K-100.2%	$12.1M+2250.2%	$517K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$102K+167.4%	$38K+118.7%	-$204K+65.9%	-$598K-1147.3%	$57K-84.9%	$379K+39.0%	$273K+201.9%	$90K
Capital Expenditures	$315K+18.0%	$267K+18.8%	$225K	N/A	N/A	$50K-6.7%	$54K+1.8%	$53K
Free Cash Flow	-$213K+6.9%	-$229K+46.6%	-$429K	N/A	N/A	$329K+50.2%	$219K+481.2%	$38K
Investing Cash Flow	-$315K-18.0%	-$267K-18.8%	-$225K	N/A	N/A	-$50K+6.7%	-$54K-1.8%	-$53K
Financing Cash Flow	$318K	$0	$0	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RMTG Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	55.1%-13.6pp	68.7%-0.8pp	69.5%+12.2pp	57.3%+23.0pp	34.3%+14.1pp	20.2%
Operating Margin	-17.0%-19.0pp	2.0%+31.7pp	-29.7%	N/A	N/A	N/A
Net Margin	-153.2%-17.8pp	-135.4%+271.8pp	-407.2%-47.3pp	-359.9%+2582.5pp	-2942.4%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-174.0%-28.5pp	-145.6%+195.3pp	-340.9%-272.7pp	-68.2%+70.3pp	-138.5%	N/A
Current Ratio	0.030.0	0.04+0.0	0.03-0.1	0.14-0.6	0.72+0.7	0.05
Debt-to-Equity	-1.13+0.0	-1.140.0	-1.13+0.5	-1.67+0.7	-2.38-1.3	-1.03
FCF Margin	-25.7%-41.1pp	15.5%+48.9pp	-33.4%+52.4pp	-85.8%	N/A	-767.5%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	66.9%+17.3pp	49.6%+7.1pp	42.5%-17.1pp	59.6%-9.6pp	69.2%+4.3pp	64.9%-10.9pp	75.7%+9.3pp	66.4%
Operating Margin	8.7%+28.2pp	-19.5%+18.3pp	-37.8%-12.3pp	-25.4%-35.3pp	9.9%-15.3pp	25.2%+23.2pp	2.0%+29.0pp	-27.0%
Net Margin	-33.2%+55.4pp	-88.6%+280.2pp	-368.8%-236.0pp	-132.8%-77.1pp	-55.7%-13.5pp	-42.2%+47.7pp	-90.0%+171.8pp	-261.8%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-17.5%+13.5pp	-31.0%+65.3pp	-96.3%-67.2pp	-29.1%-10.0pp	-19.1%-2.4pp	-16.7%	N/A	-68.1%
Current Ratio	0.040.0	0.03-0.1	0.09+0.0	0.06+0.0	0.050.0	0.04	N/A	0.03
Debt-to-Equity	-1.14-0.0	-1.13+0.0	-1.15-1.2	0.00+1.1	-1.140.0	-1.14	N/A	-1.12
FCF Margin	-8.1%+6.5pp	-14.6%+21.7pp	-36.3%	N/A	N/A	21.8%-0.4pp	22.2%+17.5pp	4.8%

Note: Shareholder equity is negative (-$34.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Emmaus Life Scie EMMA

$804K

Lobe Sciences LOBEF

$2.5M

Regen Biopharma RGBP

$51K

Braxia Scientifi BRAXF

$1.0M

Hepion Pharmaceuticals Inc HEPA

$4.3M

Frequently Asked Questions

What is Regenerative Medical Technology Group Inc's annual revenue?

Regenerative Medical Technology Group Inc (RMTG) reported $5.1M in total revenue for fiscal year 2025. This represents a 24.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Regenerative Medical Technology Group Inc's revenue growing?

Regenerative Medical Technology Group Inc (RMTG) revenue grew by 24.2% year-over-year, from $4.1M to $5.1M in fiscal year 2025.

Is Regenerative Medical Technology Group Inc profitable?

No, Regenerative Medical Technology Group Inc (RMTG) reported a net income of -$7.8M in fiscal year 2025, with a net profit margin of -153.2%.

What is Regenerative Medical Technology Group Inc's EBITDA?

Regenerative Medical Technology Group Inc (RMTG) had EBITDA of -$586K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Regenerative Medical Technology Group Inc's gross margin?

Regenerative Medical Technology Group Inc (RMTG) had a gross margin of 55.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Regenerative Medical Technology Group Inc's operating margin?

Regenerative Medical Technology Group Inc (RMTG) had an operating margin of -17.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Regenerative Medical Technology Group Inc's net profit margin?

Regenerative Medical Technology Group Inc (RMTG) had a net profit margin of -153.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Regenerative Medical Technology Group Inc's free cash flow?

Regenerative Medical Technology Group Inc (RMTG) generated -$1.3M in free cash flow during fiscal year 2025. This represents a -306.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Regenerative Medical Technology Group Inc's operating cash flow?

Regenerative Medical Technology Group Inc (RMTG) generated -$707K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Regenerative Medical Technology Group Inc's total assets?

Regenerative Medical Technology Group Inc (RMTG) had $4.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Regenerative Medical Technology Group Inc's capital expenditures?

Regenerative Medical Technology Group Inc (RMTG) invested $603K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Regenerative Medical Technology Group Inc have outstanding?

Regenerative Medical Technology Group Inc (RMTG) had 13M shares outstanding as of fiscal year 2025.

What is Regenerative Medical Technology Group Inc's current ratio?

Regenerative Medical Technology Group Inc (RMTG) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Regenerative Medical Technology Group Inc's debt-to-equity ratio?

Regenerative Medical Technology Group Inc (RMTG) had a debt-to-equity ratio of -1.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Regenerative Medical Technology Group Inc's return on assets (ROA)?

Regenerative Medical Technology Group Inc (RMTG) had a return on assets of -174.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Regenerative Medical Technology Group Inc's cash runway?

Based on fiscal year 2025 data, Regenerative Medical Technology Group Inc (RMTG) had $957K in cash against an annual operating cash burn of $707K. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Regenerative Medical Technology Group Inc's debt-to-equity ratio negative or unusual?

Regenerative Medical Technology Group Inc (RMTG) has negative shareholder equity of -$34.7M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Regenerative Medical Technology Group Inc's Altman Z-Score?

Regenerative Medical Technology Group Inc (RMTG) has an Altman Z-Score of -32.52, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Regenerative Medical Technology Group Inc's Piotroski F-Score?

Regenerative Medical Technology Group Inc (RMTG) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Regenerative Medical Technology Group Inc's earnings high quality?

Regenerative Medical Technology Group Inc (RMTG) has an earnings quality ratio of 0.09x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Regenerative Medical Technology Group Inc cover its interest payments?

Regenerative Medical Technology Group Inc (RMTG) has an interest coverage ratio of -0.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.